Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonas Busch

Showing results (51-60 of 85) with videos related to

Pageof 9
Sort By:
Aktuelle Urologie|December 20, 2017
[A retrospective analysis of functional and oncologic outcomes following surgical treatment of patients with pT1/pT2 renal cell carcinoma at a tertiary referral centre]Bernhard Ralla, Stephanie Buhl, Irena Goranova, et al.
BJU International|February 27, 2016
Significant reduction in positive surgical margin rate after laparoscopic radical prostatectomy by application of the modified surgical margin recommendations of the 2009 International Society of Urological Pathology consensusAndreas Maxeiner, Ahmed Magheli, Korinna Jöhrens, et al.
European Urology|September 25, 2012
Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinomaJonas Busch, Christoph Seidel, Barbara Erber, et al.
World Journal of Urology|January 17, 2022
Can magnetic resonance imaging replace conventional computerized tomography for follow-up of patients with testicular cancer? A systematic reviewJonas Busch, Stefanie Schmidt, Peter Albers, et al.
World Journal of Urology|April 23, 2011
Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitorsSteffen Weikert, Carsten Kempkensteffen, Jonas Busch, et al.
World Journal of Urology|May 13, 2022
How to classify, diagnose, treat and follow-up extragonadal germ cell tumors? A systematic review of available evidenceChristian Winter, Friedemann Zengerling, Jonas Busch, et al.
BJU International|October 12, 2013
Higher rates of upgrading and upstaging in older patients undergoing radical prostatectomy and qualifying for active surveillanceJonas Busch, Ahmed Magheli, Natalia Leva, et al.
International Urology and Nephrology|July 25, 2022
Evaluation of systematic prostate biopsies when performing transperineal MRI/TRUS fusion biopsy with needle tracking-what is the additional value?Karsten Günzel, Ahmed Magheli, Jonas Busch, et al.
World Journal of Urology|December 18, 2015
Efficacy of fourth-line targeted therapy in patients with metastatic renal cell carcinoma: a retrospective analysisBernhard Ralla, Barbara Erber, Irena Goranova, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|June 9, 2019
Use of quantitative T2 mapping for the assessment of renal cell carcinomas: first resultsLisa C Adams, Keno K Bressem, Phillipp Jurmeister, et al.
Pageof 9

Showing results (51-60 of 85) with videos related to

Sort By:
Pageof 9
Aktuelle Urologie|December 20, 2017
[A retrospective analysis of functional and oncologic outcomes following surgical treatment of patients with pT1/pT2 renal cell carcinoma at a tertiary referral centre]Bernhard Ralla, Stephanie Buhl, Irena Goranova, et al.
BJU International|February 27, 2016
Significant reduction in positive surgical margin rate after laparoscopic radical prostatectomy by application of the modified surgical margin recommendations of the 2009 International Society of Urological Pathology consensusAndreas Maxeiner, Ahmed Magheli, Korinna Jöhrens, et al.
European Urology|September 25, 2012
Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinomaJonas Busch, Christoph Seidel, Barbara Erber, et al.
World Journal of Urology|January 17, 2022
Can magnetic resonance imaging replace conventional computerized tomography for follow-up of patients with testicular cancer? A systematic reviewJonas Busch, Stefanie Schmidt, Peter Albers, et al.
World Journal of Urology|April 23, 2011
Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitorsSteffen Weikert, Carsten Kempkensteffen, Jonas Busch, et al.
World Journal of Urology|May 13, 2022
How to classify, diagnose, treat and follow-up extragonadal germ cell tumors? A systematic review of available evidenceChristian Winter, Friedemann Zengerling, Jonas Busch, et al.
BJU International|October 12, 2013
Higher rates of upgrading and upstaging in older patients undergoing radical prostatectomy and qualifying for active surveillanceJonas Busch, Ahmed Magheli, Natalia Leva, et al.
International Urology and Nephrology|July 25, 2022
Evaluation of systematic prostate biopsies when performing transperineal MRI/TRUS fusion biopsy with needle tracking-what is the additional value?Karsten Günzel, Ahmed Magheli, Jonas Busch, et al.
World Journal of Urology|December 18, 2015
Efficacy of fourth-line targeted therapy in patients with metastatic renal cell carcinoma: a retrospective analysisBernhard Ralla, Barbara Erber, Irena Goranova, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|June 9, 2019
Use of quantitative T2 mapping for the assessment of renal cell carcinomas: first resultsLisa C Adams, Keno K Bressem, Phillipp Jurmeister, et al.
Pageof 9